Conjunctivitis, Bacterial, Infection Associated Blepharitis, Keratitis, Ocular Inflammation
Conditions
Keywords
bacterial ocular inflammation, blepharitis, keratitis, conjunctivitis
Brief summary
To evaluate the efficacy and safety of fixed combination of azithromycin 1.5% + 0.5% Loteprednol eye drops for the treatment of ocular inflammation and infection associated bacterial blepharitis and / or keratitis and / or conjunctivitis compared with the individual administration of azithromycin 1.5% and 0.5% Loteprednol (separately).
Detailed description
Estimated to be admitted a total of approximately 60 patients showing blepharitis and / or keratitis and / or conjunctivitis: 30 patients will be assigned to the group of Azithromycin 1.5%/Loteprednol 0.5% Eye Drops (fixed combination) + placebo and 30 patients will be assigned to the group of Azithromycin 1.5% + 0.5% Loteprednol (separately)
Interventions
DRUGazithromycin 1.5%/Loteprednol 0,5% + placebo
1 drop, AO, QID
DRUGazithromycin 1.5% + Loteprednol 0,5% (separately)
1 drop, QID, AO
Sponsors
Adapt Produtos Oftalmológicos Ltda.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients were male or female, of any race and age minimum of 18 years. * Blepharitis should provide diagnostic and / or keratitis and / or conjunctivitis with or without bacterial involvement corneal by biomicroscopy, with positive staining corneal fluorescein and also provide a composite score ≥ 2 on: bulbar conjunctival hyperemia, eyelid conjunctiva, secretion / exudate conjunctival erythema and flaking eyelids / eyelid crust on at least one eye (the same eye) on Day 1 visit
Exclusion criteria
* Intraocular hypertension or uncontrolled glaucoma. * Use of contact lenses during the study. * Capacity unilateral visual only. * Suspected fungal infection, viral (eg, herpes simplex epithelial, dendritic keratitis) or Acanthamoeba, or any other disease where the use of corticosteroids is contraindicated. * Use of any topical ophthalmic medications preserved during study participation. Not be allowed eyedrops preserved (eg artificial tears). * Use of any antibacterial agent oral or topical ophthalmic until 72 hours prior to study entry. * Use of systemic steroids within 14 days prior to study entry. Ophthalmic topical steroids or nonsteroidal anti-inflammatory drugs (NSAIDs), until one week before admission to the study. Will not be allowed to use these medications during study participation. Will not be allowed to use nasal steroids during the study. Will be allowed to use inhaled steroids to aid inhaler. Will be allowed steroids dermal topics. * Use of nonsteroidal anti-inflammatory drugs (NSAIDs) systemic up to 24 hours prior to study entry or at any time during the study, unless the patient is under treatment regimen with stable (not necessary) for at least 2 months before Admission and therapy continues throughout the study. * Any disturbance or ocular or systemic disease, complicating factors or structural abnormality that affects the conduct or outcome of the study in a negative way or represents an undue risk to patient safety, according to the opinion of the investigator. * Any current immunosuppressive disorder (eg, HIV-positive), or immunosuppressive therapy (including chemotherapy). * Known allergy or suspected allergy or hypersensitivity to fluoroquinolones, to steroids or any other component of the study drug; * Pregnant or lactating. (Women of childbearing age may be admitted if they use contraception and submit urine pregnancy test negative); * Any patient who has a family member who participates in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical cure | Day 8 | Clinical cure achieved when the score of the cardinal ocular signs (hyperemia in the bulbar conjunctiva, palpebral, exudate / conjunctival discharge, eyelid erythema and flaking / crust eyelid) is zero at the time of conclusion of the study (D8) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| irradication of pathogens | Day 8 | Success obtained with microbiological irradication of pathogens present at baseline |
Other
| Measure | Time frame | Description |
|---|---|---|
| ophthalmic evaluation | Day 4 and Day 8 | decrease of visual acuity, corneal/anterior chamber changes, IOP increase and adverse event reporting |
Countries
Brazil
Outcome results
None listed